Last reviewed · How we verify
Phase I Dose Finding Study of the Orally Bioavailable Platinum Analog Satraplatin in Combination With Abraxane (Paclitaxel Protein-bound Particles) in Advanced Cancers
This is a phase I dose escalating study of oral satraplatin in combination with Abraxane administered weekly for three out of every four weeks in patients with advanced solid cancers.
Details
| Lead sponsor | Yale University |
|---|---|
| Phase | Phase 1 |
| Status | COMPLETED |
| Enrolment | 15 |
| Start date | 2007-05 |
| Completion | 2010-06 |
Conditions
- Advanced Cancers
Interventions
- Satraplatin
- Abraxane
Primary outcomes
- To determine a safe dose of oral Satraplatin to be administered for 5 consecutive days every week in combination with a 30 minute infusion of Abraxane administered weekly for 3 weeks out of 4 weeks. — Upon completion of dose escalation and determination of MTD
Countries
United States